These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 26828702)

  • 1. Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders.
    Sofuoglu M; DeVito EE; Waters AJ; Carroll KM
    J Dual Diagn; 2016; 12(1):90-106. PubMed ID: 26828702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive enhancement as a treatment for drug addictions.
    Sofuoglu M; DeVito EE; Waters AJ; Carroll KM
    Neuropharmacology; 2013 Jan; 64(1):452-63. PubMed ID: 22735770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive enhancement as a pharmacotherapy target for stimulant addiction.
    Sofuoglu M
    Addiction; 2010 Jan; 105(1):38-48. PubMed ID: 20078461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive Enhancement to Improve Substance Abuse Outcomes in Persons With Co-Occurring Disorders.
    McGurk SR
    J Dual Diagn; 2016; 12(1):72-3. PubMed ID: 26828921
    [No Abstract]   [Full Text] [Related]  

  • 5. Patterns of Substance Use During Cognitive Enhancement Therapy: An 18-Month Randomized Feasibility Study.
    Eack SM; Hogarty SS; Bangalore SS; Keshavan MS; Cornelius JR
    J Dual Diagn; 2016; 12(1):74-82. PubMed ID: 27089154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impulsivity and attentional bias as predictors of modafinil treatment outcome for retention and drug use in crack-cocaine dependent patients: Results of a randomised controlled trial.
    Nuijten M; Blanken P; Van den Brink W; Goudriaan AE; Hendriks VM
    J Psychopharmacol; 2016 Jul; 30(7):616-26. PubMed ID: 27147591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Patient-Tailored Evidence-Based Approach for Developing Early Neuropsychological Training Programs in Addiction Settings.
    Rolland B; D'Hondt F; Montègue S; Brion M; Peyron E; D'Aviau de Ternay J; de Timary P; Nourredine M; Maurage P
    Neuropsychol Rev; 2019 Mar; 29(1):103-115. PubMed ID: 30607658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive-behavioral therapies for depression and substance use disorders: An overview of traditional, third-wave, and transdiagnostic approaches.
    Vujanovic AA; Meyer TD; Heads AM; Stotts AL; Villarreal YR; Schmitz JM
    Am J Drug Alcohol Abuse; 2017 Jul; 43(4):402-415. PubMed ID: 27494547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
    Liraud F; Verdoux H
    Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive remediation in the treatment of stimulant abuse disorders: a research agenda.
    Vocci FJ
    Exp Clin Psychopharmacol; 2008 Dec; 16(6):484-97. PubMed ID: 19086769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contingency management for patients with dual disorders in intensive outpatient treatment for addiction.
    Kelly TM; Daley DC; Douaihy AB
    J Dual Diagn; 2014; 10(3):108-17. PubMed ID: 25392284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Even More Complex…. When Mental Disorder Meets Addiction in Youth: Dual Pathology.
    Torales J; Castaldelli-Maia JM; da Silva AG; Campos MW; González-Urbieta I; Barrios I
    Curr Drug Res Rev; 2019; 11(1):40-43. PubMed ID: 30829179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A transdiagnostic approach to treating sleep disturbance in psychiatric disorders.
    Harvey AG
    Cogn Behav Ther; 2009; 38 Suppl 1():35-42. PubMed ID: 19697179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cocaine addiction as a neurological disorder: implications for treatment.
    Majewska MD
    NIDA Res Monogr; 1996; 163():1-26. PubMed ID: 8809851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychopharmacotherapy for addictive and comorbid disorders: current studies.
    Pechter BM; Miller NS
    J Addict Dis; 1997; 16(4):23-40. PubMed ID: 9328807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mindful neuropsychology: Mindfulness-based cognitive remediation].
    Bulzacka E; Lavault S; Pelissolo A; Bagnis Isnard C
    Encephale; 2018 Feb; 44(1):75-82. PubMed ID: 28483271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognition enhancers between treating and doping the mind.
    Lanni C; Lenzken SC; Pascale A; Del Vecchio I; Racchi M; Pistoia F; Govoni S
    Pharmacol Res; 2008 Mar; 57(3):196-213. PubMed ID: 18353672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive enhancers in the treatment of substance use disorders: clinical evidence.
    Brady KT; Gray KM; Tolliver BK
    Pharmacol Biochem Behav; 2011 Aug; 99(2):285-94. PubMed ID: 21557964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods for delivering and evaluating the efficacy of cognitive enhancement.
    Harvey PD; Keefe RS
    Handb Exp Pharmacol; 2015; 228():5-25. PubMed ID: 25977078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dual diagnosis psychosis and substance use disorders in adolescents--part 2].
    Meister K; Rietschel L; Burlon M; Gouzoulis-Mayfrank E; Bock T; Lambert M
    Fortschr Neurol Psychiatr; 2010 Feb; 78(2):90-100. PubMed ID: 20146153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.